
News|Articles|October 1, 2012
Tofacitinib: A novel oral Janus kinase inhibitor for rheumatoid arthritis
Tofacitinib is a novel JAK inhibitor, selective for JAK 1 and JAK 3.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
FDA issues draft guidance on MRD and complete response as primary endpoints for accelerated multiple myeloma drug approvals
3
Cancer survival fell and deaths rose during first two years of COVID-19
4
TrumpRx launches; some experts question its long-term value
5























